A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China

Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation

(2020) Yaling Du et al.   Expert Review of Pharmacoeconomics & Outcomes Research

60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments

(2020) Marco Kaufmann et al.   Frontiers in Neurology

Economic burden of smoking-attributable diseases in China: A systematic review

(2020) Lili Shi et al.   Tobacco Induced Diseases

Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia

(2018) Saima Nazish et al.   Journal of Clinical Neurology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Hmwe Hmwe Kyu et al.   LANCET

Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

(2017) Daniel M. Hartung   Neurotherapeutics

Pathophysiology, assessment and management of multiple sclerosis fatigue: an update

(2016) Mariarosa Rottoli et al.   Expert Review of Neurotherapeutics

Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China

(2016) Xiao Liu et al.   Orphanet Journal of Rare Diseases

Pathophysiology, assessment and management of multiple sclerosis fatigue: an update

(2016) Mariarosa Rottoli et al.   Expert Review of Neurotherapeutics

The indirect costs of multiple sclerosis: systematic review and meta-analysis

(2015) Ewa Stawowczyk et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses

(2015) Gregory J. Esper et al.   JAMA Neurology

Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

(2015) Alberto Gajofatto et al.   World Journal of Clinical Cases

Incidence, Prevalence, Costs, and Impact on Disability of Common Conditions Requiring Rehabilitation in the United States: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Limb Loss, and Back Pain

(2014) Vincent Y. Ma et al.   ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta

(2013) Florian Castrop et al.   Neuropsychiatric Disease and Treatment

The cost burden of multiple sclerosis in the United States: a systematic review of the literature

(2013) Gabriel Adelman et al.   JOURNAL OF MEDICAL ECONOMICS

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Christopher J L Murray et al.   LANCET

Pathology of Demyelinating Diseases

(2011) Bogdan F.Gh. Popescu et al.   Annual Review of Pathology-Mechanisms of Disease

The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US

(2010) Jasmina I. Ivanova et al.   PHARMACOECONOMICS